Functional and Clinical Proteomic Exploration of Pancreatic Cancer

Huang，Peiwu; Gao，Weina; Fu，Changying; Tian，Ruijun

2023-07-01

10.1016/j.mcpro.2023.100575

Molecular and Cellular Proteomics   Impact Factor & Quartile

1535-9476

1535-9484

Pancreatic cancer, in most cases being pancreatic ductal adenocarcinoma (PDAC), is one of the most lethal cancers with a median survival time of less than 6 months. Therapeutic options are very limited for patients with PDAC, and surgery is still the most effective treatment, making improvements in early diagnosis critical. One typical characteristic of PDAC is the desmoplastic reaction of its stroma microenvironment, which actively interacts with cancer cells to orchestrate key components in tumorigenesis, metastasis, and chemoresistance. A global exploration of cancer-stroma crosstalk is essential to decipher PDAC biology and design intervention strategies. Over the past decade, the dramatic improvement in proteomics technologies has enabled the profiling of proteins, post-translational modifications (PTMs), and their protein complexes at unprecedented sensitivity and dimensionality. Here, starting with our current understanding of PDAC characteristics, including precursor lesions, progression models, tumor microenvironment, and therapeutic advancements, we describe how proteomics contributes to the functional and clinical exploration of PDAC, providing insights into PDAC carcinogenesis, progression, and chemoresistance. We summarize recent achievements enabled by proteomics to systematically investigate PTMs-mediated intracellular signaling in PDAC, cancer-stroma interactions, and potential therapeutic targets revealed by these functional studies. We also highlight proteomic profiling of clinical tissue and plasma samples to discover and verify useful biomarkers that can aid early detection and molecular classification of patients. In addition, we introduce spatial proteomic technology and its applications in PDAC for deconvolving tumor heterogeneity. Finally, we discuss future prospects of applying new proteomic technologies in comprehensively understanding PDAC heterogeneity and intercellular signaling networks. Importantly, we expect advances in clinical functional proteomics for exploring mechanisms of cancer biology directly by high-sensitivity functional proteomic approaches starting from clinical samples.

English

First ; Corresponding

Science, Technology and Innovation Commission of Shenzhen Municipality[2019B151502050];National Key Research and Development Program of China[2020YFE0202200];National Key Research and Development Program of China[2021YFA1301601];National Key Research and Development Program of China[2021YFA1301602];National Key Research and Development Program of China[2021YFA1302603];National Natural Science Foundation of China[22,004,056];National Natural Science Foundation of China[22,104,047];National Natural Science Foundation of China[22,125,403];National Natural Science Foundation of China[32,171,433];National Natural Science Foundation of China[91,953,118];Science, Technology and Innovation Commission of Shenzhen Municipality[JCYJ20200109140814408];Science, Technology and Innovation Commission of Shenzhen Municipality[JCYJ20200109141212325];Science, Technology and Innovation Commission of Shenzhen Municipality[JCYJ20210324120210029];

MOLECULAR BIOLOGY & GENETICS

2-s2.0-85165521453

Scopus

Department of Chemistry,Research Center for Chemical Biology and Omics Analysis,School of Science,Southern University of Science and Technology,Shenzhen,China

Huang，Peiwu,Gao，Weina,Fu，Changying,et al. Functional and Clinical Proteomic Exploration of Pancreatic Cancer[J]. Molecular and Cellular Proteomics,2023,22(7).

Huang，Peiwu,Gao，Weina,Fu，Changying,&Tian，Ruijun.(2023).Functional and Clinical Proteomic Exploration of Pancreatic Cancer.Molecular and Cellular Proteomics,22(7).

Huang，Peiwu,et al."Functional and Clinical Proteomic Exploration of Pancreatic Cancer".Molecular and Cellular Proteomics 22.7(2023).